Abstract
Candida species are the fourth most common cause of nosocomial bloodstream infections. An increase in the frequency of infections which have become refractory to standard antifungal therapyhave been observed. Recently, the effect of different organochalcogenide compounds reducing both growth and germ tube formation by Candida albicans was demonstrated. This work studied the effect of the organochalcogenide compound (pCl-PhSe)2 on both growth and biofilm formation by Candida albicans. A decrease in C. albicans growth in the presence of crescent concentrations of (pCl- PhSe)2 was observed, in a cell density dependent manner. The inhibition of Candida growth by 10µM (pCl-PhSe)2 was ~60, 57, 47 and 24%, in cell densities of 103, 104, 105 and 106 cells/ml, respectively. The compound (pCl-PhSe)2 was able to inhibit biofilm formation by Candida albicans, when biofilm was performed using a cell density of 106 cells/ml. In addition, an increase in both ROS production (96%) and cell membrane permeability (1.107-fold) by 10 µM (pCl-PhSe)2 was observed in C. albicans.These results demonstrate that the organochalcogenide compound (pCl-PhSe)2 presents a great potential to inhibit both growth and biofilm formation by C. albicans.
Keywords: Candida albicans, biofilm, antifungal therapy, organochalcogenide compound, (pCl-PhSe)2.
Current Drug Discovery Technologies
Title:Biofilm Formation by Candida albicans is Inhibited by 4,4-Dichloro Diphenyl Diselenide (pCl-PhSe)2
Volume: 11 Issue: 3
Author(s): Isabela Bueno Rosseti, Paulo Taube Junior, Claudia Barbosa Ladeira de Campos, Joao Batista Teixeira da Rocha and Maricilia Silva Costa
Affiliation:
Keywords: Candida albicans, biofilm, antifungal therapy, organochalcogenide compound, (pCl-PhSe)2.
Abstract: Candida species are the fourth most common cause of nosocomial bloodstream infections. An increase in the frequency of infections which have become refractory to standard antifungal therapyhave been observed. Recently, the effect of different organochalcogenide compounds reducing both growth and germ tube formation by Candida albicans was demonstrated. This work studied the effect of the organochalcogenide compound (pCl-PhSe)2 on both growth and biofilm formation by Candida albicans. A decrease in C. albicans growth in the presence of crescent concentrations of (pCl- PhSe)2 was observed, in a cell density dependent manner. The inhibition of Candida growth by 10µM (pCl-PhSe)2 was ~60, 57, 47 and 24%, in cell densities of 103, 104, 105 and 106 cells/ml, respectively. The compound (pCl-PhSe)2 was able to inhibit biofilm formation by Candida albicans, when biofilm was performed using a cell density of 106 cells/ml. In addition, an increase in both ROS production (96%) and cell membrane permeability (1.107-fold) by 10 µM (pCl-PhSe)2 was observed in C. albicans.These results demonstrate that the organochalcogenide compound (pCl-PhSe)2 presents a great potential to inhibit both growth and biofilm formation by C. albicans.
Export Options
About this article
Cite this article as:
Rosseti Bueno Isabela, Junior Taube Paulo, Campos Barbosa Ladeira de Claudia, Rocha Batista Teixeira da Joao and Costa Silva Maricilia, Biofilm Formation by Candida albicans is Inhibited by 4,4-Dichloro Diphenyl Diselenide (pCl-PhSe)2, Current Drug Discovery Technologies 2014; 11 (3) . https://dx.doi.org/10.2174/1570163811666140924121758
DOI https://dx.doi.org/10.2174/1570163811666140924121758 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotection Abilities of Cytosolic Phospholipase A2 Inhibitors in Kainic acid-induced Neurodegeneration
Current Drug Targets - Cardiovascular & Hematological Disorders The Dynamic TRPA1 Channel: A Suitable Pharmacological Pain Target?
Current Pharmaceutical Biotechnology Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience Combination of Therapeutic Hypothermia and Other Neuroprotective Strategies after An Ischemic Cerebral Insult
Current Neuropharmacology The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders
Current Pharmaceutical Design Mesenchymal Stem Cells Neuronal Differentiation Ability: A Real Perspective for Nervous System Repair?
Current Stem Cell Research & Therapy Selective Neuronal Nitric Oxide Synthase Inhibitors
Current Topics in Medicinal Chemistry Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging
Current Medicinal Chemistry A Role of GABA Analogues in the Treatment of Neurological Diseases
Current Medicinal Chemistry Metabotropic Glutamate Receptors in the Trafficking of Ionotropic Glutamate and GABAA Receptors at Central Synapses
Current Neuropharmacology L-Arginine Analogs – Inactive Markers or Active Agents in Atherogenesis?
Cardiovascular & Hematological Agents in Medicinal Chemistry Regional Pharmacokinetics of Orally Administered PET Tracers
Current Pharmaceutical Design A Dual Activity of ROS and Oxidative Stress on Adult Neurogenesis and Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Molecular and Cellular Control of Dendrite Maturation During Brain Development
Current Molecular Pharmacology Ginkgo biloba Extract 761: A Review of Basic Studies and Potential Clinical Use in Psychiatric Disorders
CNS & Neurological Disorders - Drug Targets Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders
CNS & Neurological Disorders - Drug Targets Good Epidemiologic Practice in Retinitis Pigmentosa: From Phenotyping to Biobanking
Current Genomics Immunotherapy Strategies for Spinal Cord Injury
Current Pharmaceutical Biotechnology Presynaptic NR2B-Containing NMDA Autoreceptors Mediate Glutamatergic Synaptic Transmission in the Rat Visual Cortex
Current Neurovascular Research